DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP), a biopharmaceutical company focused on infectious disease and dermatology, today reported it has completed the patient visit phase of its clinical study evaluating the efficacy of the company’s EpiCeram in comparison to a mid-strength topical steroid in treating patients with moderate to severe atopic dermatitis (eczema).
